Open AccessP1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI‐ARM PHASE 1B STUDY
Author(s) -
Soumerai J. D.,
Jagadeesh D.,
Salman H.,
Samaniego F.,
Patel K.,
Stathis A.,
Reddy N.,
Kenkre V. P.,
Asch A.,
Diefenbach C.,
Lossos I. S.,
Persky D.,
Awan F.,
Huang W.,
Vandever K.,
Zelenetz A. D.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847324.06186.df
Subject(s) - medicine , dosing , rituximab , adverse effect , follicular lymphoma , refractory (planetary science) , oncology , phases of clinical research , progressive disease , pharmacology , gastroenterology , lymphoma , chemotherapy , physics , astrobiology